Advertisement
Organisation › Details
Polaris (NO) (Group)
Targovax is an Oslo-area based global biotechnology company, dedicated to the design and development of immunotherapy vaccines for patients with RAS-mutated cancers. Established in 2010 by the inventors of this RAS-targeted technology and the Norwegian Radium Hospital Research Foundation in Oslo, Targovax has over 25 years of direct experience and has seen more than 250 patients treated with this promising technology. *
Start | 2015-06-11 merged | |
Predecessor | Targovax ASA (OSE: TRVX) | |
Industry | TG01 (Targovax) | |
Industry 2 | therapeutic vaccine | |
Person | Gårdemyr, Gunnar (Follicum 201902 before Targovax/Polaris + Nycomed/Takeda) | |
Person 2 | Øystein, Soug (Polaris 201506 announced as CFO before Algeta + Orcla) | |
Region | Lysaker | |
Country | Norway | |
City | n. a. | |
Address record changed: 2015-06-21 | ||
Basic data | Employees | B: 11 to 50 (2015-06-11) |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top